M Guy, Z Kote-Jarai, GG Giles, AA Al Olama, SK Jugurnauth, S Mulholland, DA Leongamornlert, SM Edwards, J Morrison, HI Field, MC Southey, G Severi, JL Donovan, FC Hamdy, DP Dearnaley, KR Muir, C Smith, M Bagnato, AT Ardern-Jones, AL Hall, LT O'Brien, BN Gehr-Swain, RA Wilkinson, A Cox, S Lewis, PM Brown, SG Jhavar, M Tymrakiewicz, A Lophatananon, SL Bryant, UK Genetic Prostate Cancer Study Collaborators, British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators, A Horwich, RA Huddart, VS Khoo, CC Parker, CJ Woodhouse, A Thompson, T Christmas, C Ogden, C Fisher, C Jameson, CS Cooper, DR English, JL Hopper, DE Neal, DF Easton, RA Eeles
Asian J Androl
There is evidence that a substantial part of genetic predisposition to prostate cancer (PCa) may be due to lower penetrance genes which are found by genome-wide association studies. We have recently conducted such a study and seven new regions of the genome linked to PCa risk have been identified. Three of these loci contain candidate susceptibility genes: MSMB, LMTK2 and KLK2/3. The MSMB and KLK2/3 genes may be useful for PCa screening, and the LMTK2 gene might provide a potential therapeutic target. Together with results from other groups, there are now 23 germline genetic variants which have been reported. These results have the potential to be developed into a genetic test. However, we consider that marketing of tests to the public is premature, as PCa risk can not be evaluated fully at this stage and the appropriate screening protocols need to be developed. Follow-up validation studies, as well as studies to explore the psychological implications of genetic profile testing, will be vital prior to roll out into healthcare.